Dipeptide nitrile cathepsin K inhibitors
    3.
    发明授权
    Dipeptide nitrile cathepsin K inhibitors 失效
    二肽腈组织蛋白酶K抑制剂

    公开(公告)号:US06642239B2

    公开(公告)日:2003-11-04

    申请号:US09778302

    申请日:2001-02-07

    申请人: Martin Missbach

    发明人: Martin Missbach

    IPC分类号: C07D29514

    摘要: Dipeptide nitrile Cathepsin K inhibitors of formula I, and pharmaceutically acceptable salts or esters thereof: In which R1 and R2 are independently H or C1-C7lower alkyl, or R1 and R2 together with the carbon atom to which they are attached form a C3-C8cycloalkyl ring, and Het is an optionally substituted nitrogen-containing heterocyclic substituent, are provided, useful e.g. for therapeutic or prophylactic treatment of a disease or medical condition in which cathepsin K is implicated.

    摘要翻译: 式I的二肽腈组织蛋白酶K抑制剂及其药学上可接受的盐或酯:其中R1和R2独立地为H或C1-C7低级烷基,或R1和R2与它们所连接的碳原子一起形成C 3 -C 8环烷基环 ,并且Het是任选取代的含氮杂环取代基,例如有用 用于治疗或预防治疗涉及组织蛋白酶K的疾病或医学病症。

    Pyrrolo�2,3-d!pyrimidines and their use
    5.
    发明授权
    Pyrrolo�2,3-d!pyrimidines and their use 失效
    吡咯并[2,3-d]嘧啶及其用途

    公开(公告)号:US5869485A

    公开(公告)日:1999-02-09

    申请号:US793313

    申请日:1997-03-19

    申请人: Martin Missbach

    发明人: Martin Missbach

    CPC分类号: C07D487/04

    摘要: The invention relates to the use of the compounds mentioned below in the therapeutic treatment of tumor diseases and other proliferative diseases, such as psoriasis, and to novel compounds of that type. The compounds are compounds of formula I ##STR1## wherein n is from 0 to 5 and, when n is not 0,R is one or more substituents selected from halogen, alkyl, trifluoromethyl and alkoxy; andR.sub.1 and R.sub.2 are each independently of the other alkyl, or phenyl that is unsubstituted or substituted by halogen, trifluoromethyl, alkyl or by alkoxy, it also being possible for one of the two radicals R.sub.1 and R.sub.2 to be hydrogen, or R1 and R2 together form an alkylene chain having from 2 to 5 carbon atoms that is unsubstituted or substituted by alkyl; or salts thereof. Compounds of formula I inhibit protein kinases, for example the tyrosine protein kinase of the receptor for the epidermal growth factor, EGF.

    摘要翻译: PCT No.PCT / EP95 / 03536 Sec。 371日期1997年3月19日 102(e)1997年3月19日PCT PCT 1995年9月8日PCT公布。 出版物WO96 / 日期1996年4月4日本发明涉及下述化合物在治疗肿瘤疾病和其它增殖性疾病如牛皮癣的治疗中的用途,以及该类型的新型化合物。 化合物是式I的化合物,其中n不为0,R为一个或多个选自卤素,烷基,三氟甲基和烷氧基的取代基; 并且R 1和R 2各自独立地为未被取代或被卤素,三氟甲基,烷基或烷氧基取代的苯基,也可以是两个基团R 1和R 2中的一个为氢,或者R 1和R 2 一起形成未被取代或被烷基取代的具有2至5个碳原子的亚烷基链; 或其盐。 式I的化合物抑制蛋白激酶,例如表皮生长因子受体的酪氨酸蛋白激酶EGF。

    Substituted thiosemicarbazone derivatives
    6.
    发明授权
    Substituted thiosemicarbazone derivatives 失效
    取代的缩氨基硫脲衍生物

    公开(公告)号:US5641776A

    公开(公告)日:1997-06-24

    申请号:US500987

    申请日:1995-07-25

    申请人: Martin Missbach

    发明人: Martin Missbach

    CPC分类号: C07D417/12 C07D279/06

    摘要: The present invention relates to novel substituted thiosemicarbazone derivatives of formula (I) wherein R.sub.1 is lower alkyl, lower alk-2-en-1-yl, lower alk-2-yn-1-yl, or aryl-lower alkyl, R.sub.2 is hydrogen, lower alkyl, aryl, aryl-lower alkyl, lower alk-2-en-1-yl, lower alk-2-yn-1-yl, unsaturated or saturated heterocyclyl-lower alkyl, lower alkoxycarbonyl-lower alkyl or the group --C(.dbd.O)--R.sub.3, wherein R.sub.3 is lower alkyl, aryl, aryl-lower alkyl, aryl-lower alkenyl, heteroaryl (betaryl), aryloxy, aryl-lower alkoxy or lower alk-2-en-1-yloxy, and the salts thereof, to a process for the preparation of said compounds, to pharmaceutical compositions containing them, and to the use thereof as medicaments. ##STR1##

    摘要翻译: PCT No.PCT / EP94 / 03679 371日期:1995年7月25日 102(e)日期1995年7月25日PCT 1994年11月9日PCT PCT。 WO95 / 14685 PCT公开 日期:1995年6月1日本发明涉及式(I)的新型取代缩氨基硫脲衍生物,其中R 1为低级烷基,低级烷-2-烯-1-基,低级烷-2-炔-1-基或芳基 - 低级烷基,R2是氢,低级烷基,芳基,芳基 - 低级烷基,低级烯-2-烯-1-基,低级烷-2-炔-1-基,不饱和或饱和的杂环基 - 低级烷基,低级烷氧基羰基 - 低级烷基或基团-C(= O)-R 3,其中R 3是低级烷基,芳基,芳基 - 低级烷基,芳基 - 低级烯基,杂芳基(芳芳基),芳氧基,芳基 - 低级烷氧基或低级烷-2-烯 -1-基氧基及其盐与制备所述化合物的方法,含有它们的药物组合物及其作为药物的用途。 (一)

    Benzopyranone compounds, compositions thereof, and methods of treatment therewith
    8.
    发明授权
    Benzopyranone compounds, compositions thereof, and methods of treatment therewith 失效
    苯并吡喃酮化合物,其组合物及其处理方法

    公开(公告)号:US07247646B2

    公开(公告)日:2007-07-24

    申请号:US10942519

    申请日:2004-09-15

    CPC分类号: C07D311/16 C07D311/14

    摘要: Benzopyranone Compounds having the following structure: wherein R1, R2, X, Y and n are as defined herein, are disclosed. The Benzopyranone Compounds are useful for treating or preventing a bone-resorbing disease, a neoplastic disease, arthritis, a disease exacerbated by the presence of estrogen or a disease improved by the presence of estrogen, comprising administering an effective amount of a Benzopyranone Compound to a patient in need of the treating or preventing; activating the function of estrogen receptor (“ER”) in a bone cell; inhibiting the function of ER in a cancer cell; inhibiting the expression of interleukin-6 (“IL-6”) in a cell; and inhibiting the growth of a neoplastic cell, comprising contacting the cell with an effective amount of a Benzopyranone Compound.

    摘要翻译: 苯并吡喃酮具有以下结构的化合物:其中R 1,R 2,X,Y和n如本文所定义。 苯并吡喃酮化合物可用于治疗或预防骨吸收疾病,肿瘤性疾病,关节炎,由雌激素的存在或由雌激素的存在而改善的疾病而加重的疾病,包括将有效量的苯并吡喃酮化合物给予 需要治疗或预防的患者; 激活骨细胞中雌激素受体(“ER”)的功能; 抑制ER在癌细胞中的功能; 抑制细胞中白细胞介素-6(“IL-6”)的表达; 并抑制肿瘤细胞的生长,包括使细胞与有效量的苯并吡喃酮化合物接触。

    Imidazoles
    9.
    发明授权
    Imidazoles 失效
    咪唑

    公开(公告)号:US5378719A

    公开(公告)日:1995-01-03

    申请号:US196880

    申请日:1994-02-15

    申请人: Martin Missbach

    发明人: Martin Missbach

    CPC分类号: C07D417/12

    摘要: Novel imidazoles of formula I ##STR1## wherein R.sub.1 and R.sub.4 are lower alkyl, lower alk-2-en-1-yl or lower alk-2-yn-1-yl,R.sub.2 and R.sub.3 are each independently of the other hydrogen or lower alkyl or together form lower alkylidene, andR.sub.5 and R.sub.6 are each hydrogen or lower alkyl or together form oxo, andR.sub.5 ' and R.sub.6 ' have the same definitions as R.sub.5 and R.sub.6,with the proviso that at least one of the substituent pairs R.sub.5 and R.sub.6 or R.sub.5 ' and R.sub.6 ' together form oxo, and salts thereof, processes for the preparation of the said compounds, pharmaceutical compositions comprising them and the use thereof as medicinal active ingredients.

    摘要翻译: 式I的新型咪唑其中R1和R4是低级烷基,低级烯-2-烯-1-基或低级烷-2-炔-1-基,R2和R3各自独立地为另一个 氢或低级烷基或一起形成低级亚烷基,R 5和R 6各自为氢或低级烷基或一起形成氧代,并且R 5'和R 6'具有与R 5和R 6相同的定义,条件是至少一个取代基 对R5和R6或R5'和R6'一起形成氧代及其盐,制备所述化合物的方法,包含它们的药物组合物及其作为药用活性成分的用途。